Loading...
India's atovaquone imports from CHINA total $79 across 1 shipments from 1 foreign suppliers. RUBIN CHEMISTS leads with $79 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include AUROBINDO PHARMA LTD. This corridor reflects India's pharmaceutical import demand for atovaquone — a concentrated sourcing relationship with select suppliers from CHINA.
RUBIN CHEMISTS is the leading Atovaquone supplier from CHINA to India, with import value of $79 across 1 shipments. The top 5 suppliers — RUBIN CHEMISTS — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | RUBIN CHEMISTS | $79 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD | $79 | 1 | 100.0% |
CHINA → India trade corridor intelligence
As of April 2026, the China to India pharmaceutical trade corridor remains active, with no significant disruptions reported. Port congestion at major Indian ports such as Jawaharlal Nehru Port (JNPT), Chennai, and Mundra is minimal, facilitating efficient logistics. Freight rates have stabilized, and the exchange rate between the Indian Rupee (INR) and Chinese Yuan (CNY) remains favorable for trade.
The Indian government's emphasis on self-reliance, as articulated in the "Atmanirbhar Bharat" initiative, has led to increased focus on domestic pharmaceutical production. However, the importation of certain finished formulations, including those containing Atovaquone, continues due to specific market needs and the lack of domestic manufacturing capabilities for these products. The Production-Linked Incentive (PLI) scheme aims to boost domestic manufacturing, but its impact on finished formulation imports from China is yet to be fully realized.
India and China maintain a complex trade relationship, with ongoing discussions on Free Trade Agreements (FTAs) and mutual recognition of Good Manufacturing Practices (GMP). These negotiations aim to facilitate pharmaceutical trade by ensuring product quality and regulatory compliance. The mutual recognition of GMP standards is a key area of focus to streamline the import process and enhance trade efficiency.
The landed cost of importing finished Atovaquone formulations from China to India includes the following components:
The total landed duty is approximately 23.536% of the CIF value.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Atovaquone into India, the importer must obtain an Import Registration and License from the Central Drugs Standard Control Organization (CDSCO), as mandated by the Drugs and Cosmetics Act and associated rules. This process involves submitting an application to CDSCO, providing detailed product information, and ensuring compliance with the New Drugs and Clinical Trials (NDCT) Rules 2019. The registration certificate and import license are essential for the legal import and distribution of pharmaceutical products in India. The timeline for obtaining these approvals can vary, but it typically ranges from several weeks to a few months, depending on the completeness of the application and the regulatory workload.
Imported pharmaceutical formulations containing Atovaquone must undergo quality testing at CDSCO-approved laboratories in India. This includes batch-wise testing to verify the product's quality, safety, and efficacy. A Certificate of Analysis (CoA) is required for each batch, along with stability data demonstrating compliance with International Council for Harmonisation (ICH) guidelines, particularly for ICH Zone IV conditions. The product must also meet the standards set forth in the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to ensure compliance with these requirements.
In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations containing Atovaquone. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The regulations stipulate that both approved and unapproved new drugs manufactured in Special Economic Zones (SEZs) must comply with the NDCT Rules 2019 and the Drugs Rules 1945. Additionally, the importation of bulk packs of APIs, semi-finished, or finished dosage forms without the necessary import license and registration certificate is prohibited for distribution and sale in the domestic market.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Atovaquone formulations primarily due to the need for patented or branded products, specific dosage forms, and formulations not manufactured domestically. The domestic pharmaceutical industry may lack the capacity or technology to produce certain Atovaquone formulations, leading to reliance on imports. The market size for Atovaquone formulations in India is substantial, with total exports amounting to $990.7 million across 17 exporters to 21 countries. This indicates a significant demand for Atovaquone formulations, both domestically and internationally.
The Basic Customs Duty (BCD) for HS Code 30049099, which covers finished pharmaceutical formulations containing Atovaquone, is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on imports. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied. The total landed duty, combining these charges, is approximately 23.536%.
China's competitive position as a source for finished Atovaquone formulations to India is influenced by factors such as patent expirations, specialized dosage forms, and cost advantages. Chinese manufacturers may offer formulations that are not available domestically, providing a unique value proposition. While other countries like Germany and the United States also supply Atovaquone formulations, China's share in the Indian market is notable due to these competitive advantages.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Atovaquone formulations from China due to the availability of patented or branded products, specific dosage forms, and formulations not manufactured domestically. Chinese manufacturers may offer unique formulations or cost advantages that are not available from domestic suppliers, fulfilling specific market needs in India.
When comparing China to other origins such as the European Union and the United States, China offers competitive pricing and a range of formulations that may not be available elsewhere. While the EU and the US are known for high-quality products, China's ability to provide cost-effective solutions and unique formulations makes it a valuable source for finished Atovaquone formulations.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory changes in China, highlighting the importance of risk management strategies.
Import license checklist, document requirements, quality testing, and compliance
6.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Atovaquone suppliers from CHINA to India include RUBIN CHEMISTS. The leading supplier is RUBIN CHEMISTS with import value of $79 USD across 1 shipments. India imported Atovaquone worth $79 USD from CHINA in total across 1 shipments.
India imported Atovaquone worth $79 USD from CHINA across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Atovaquone sourced from CHINA include AUROBINDO PHARMA LTD. The largest buyer is AUROBINDO PHARMA LTD with $79 in imports across 1 shipments.
The total value of Atovaquone imports from CHINA to India is $79 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists